Медицинская библиотека · Thrombosis journal · 2022

LMWHs dosage and outcomes in acute pulmonary embolism with renal insufficiency, an analysis from a large real-world study.

Wang Dingyi, Fan Guohui, Lei Jieping, Yang Yuanhua, Xu Xiaomao, Ji Yingqun, Yi Qun, Chen Hong, Hu Xiaoyun, Liu Zhihong, Mao Yimin, Zhang Jie, Shi Juhong, Zhang Zhu, Wu Sinan, Tao Xincao, Xie Wanmu, Wan Jun, Zhang Yunxia, Zhang Shuai, Zhen Kaiyuan, Zhang Zhonghe, Fang Baomin, Wang Chen, Zhai Zhenguo, China pUlmonary thromboembolism REgistry Study (CURES) investigators

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Renal function is associated with prognoses for acute pulmonary embolism (PE).

OBJECTIVE

To investigate the application of anticoagulants and dosage of LMWH among patients with renal insufficiency (RI), and the association between LWMH dosage and the patients' in-hospital outcomes.

METHODS

Adult patients diagnosed with non-high risk acute PE from 2009 to 2015, with available data of creatinine clearance (CCr) were enrolled from a multicenter registry in China. Renal insufficiency (RI) was defined as CCr < 60 ml/min. LMWH dosage was converted into IU/kg daily dose and presented as adjusted dose (≤ 100 IU/kg/day) and conventional dose (> 100 IU/kg/day). All-cause death, PE-related death and bleeding events during hospitalization were analyzed as endpoints.

RESULTS

Among the enrolled 5870 patients, RI occurred in 1311 (22.3%). 30 ≤ CCr < 60 ml/min was associated with higher rate of bleeding events and CCr < 30 ml/min was associated with all-cause death, PE-related death and major bleeding. Adjusted-dose LMWH was applied in 26.1% of patients with 30 ≤ CCr < 60 ml/min and in 26.2% of CCr < 30 ml/min patients. Among patients with RI, in-hospital bleeding occurred more frequently in those who were administered conventional dose of LMWH, compared with adjusted dose (9.2% vs 5.0%, p = 0.047). Adjusted dose of LMWH presented as protective factor for in-hospital bleeding (OR 0.62, 95%CI 0.27-1.00, p = 0.0496) and the risk of bleeding increased as length of hospital stay prolonged (OR 1.03, 95%CI 1.01-1.06, p = 0.0014).

CONCLUSIONS

The proportion of adjusted usage of LMWH was low. The application of adjusted-dose LMWH was associated with lower risk of in-hospital bleeding for RI patients, in real-world setting of PE treatment. Anticoagulation strategy for RI patients should be paid more attention and requires evidence of high quality.

TRIAL REGISTRATION: The CURES was registered in ClinicalTrias.gov, identifier number: NCT02943343 .

Для цитирования: Wang Dingyi, Fan Guohui, Lei Jieping, Yang Yuanhua, Xu Xiaomao, Ji Yingqun, Yi Qun, Chen Hong, Hu Xiaoyun, Liu Zhihong, Mao Yimin, Zhang Jie, Shi Juhong, Zhang Zhu, Wu Sinan, Tao Xincao, Xie Wanmu, Wan Jun, Zhang Yunxia, Zhang Shuai, Zhen Kaiyuan, Zhang Zhonghe, Fang Baomin, Wang Chen, Zhai Zhenguo, China pUlmonary thromboembolism REgistry Study (CURES) investigators. LMWHs dosage and outcomes in acute pulmonary embolism with renal insufficiency, an analysis from a large real-world study.. Thrombosis journal. 2022. DOI: 10.1186/s12959-022-00385-z.

Подготовка и перевод публикации

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.